CA
TARA icon

Clearstead Advisors’s Protara Therapeutics TARA Stock Holding History

Clearstead Advisors’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12 Buy
+3
New +$14 ﹤0.01% 3614

Other funds holding TARA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
OC
Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Clearstead Advisors's TARA Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Protara Therapeutics (TARA) in Q2 2026: 3 shares worth $12. The stake represents ﹤0.01% of the portfolio and ranks #3614 among its holdings.

33 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • Clearstead Advisors held 3 shares of Protara Therapeutics worth $12 as of Q2 2026.
  • Protara Therapeutics was a new Clearstead Advisors position in Q2 2026.
  • Protara Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3614 holding.
  • 33 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.